Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LPCN
#3478
Lipocine Inc.
9.960
0
+4.73%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
+4.73%
Monthly Change
-0.10%
6 month change
+243.45%
Cambio anual
+243.45%
Cierres anteriores
9.510
0
Open
9.960
0
Bid
Ask
Low
9.960
0
High
9.960
0
Volumen
6
Markets
Acciones
Atención Sanitaria
LPCN
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
5.35 M
5.35 M
5.35 M
5.42 M
5.55 M
—
Valuation ratios
Enterprise value
20.27 M
19.9 M
13.66 M
11.08 M
11.92 M
56.57 M
Price to earnings ratio
-5.83
—
-3.15
-3.67
-2.82
—
Price to sales ratio
3.04
2.36
4.69
4.06
3.57
14.68
Price to cash flow ratio
-4.87
-21.67
-3.05
-3.37
-2.96
-31.05
Price to book ratio
0.28
1.26
0.21
0.22
0.21
1.91
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.11
0.08
-0.09
-0.12
-0.2
-0.33
Return on equity %
-0.12
0.08
-0.1
-0.13
-0.23
-0.37
Return on invested capital %
-4 550.42
1 749.28
-1 668.85
-1 982.14
-2 859.92
-4 761.62
Gross margin %
0
100
100
100
100
400
Operating margin %
263.05 M
44.27
-2 226.82
-386.03
-2 933.51
-5 502.09
EBITDA margin %
—
—
—
—
—
—
Net margin %
221.88 M
51.04
-1 986.78
-354.13
-2 781.46
-5 071.33
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
12.97
14.75
15.64
12.71
8.25
51.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.16
0
0.03
0.01
0.2
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.53
0.31
-0.37
-0.35
-0.55
-0.96
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
3.71
3.99
3.69
3.35
2.8
13.82
Net current asset value per share
3.83
4.12
3.8
3.44
2.94
14.3
Tangible book value per share
3.57
3.87
3.59
3.2
2.61
13.27
Working capital per share
3.54
3.84
3.56
3.17
2.59
13.15
Book value per share
3.57
3.87
3.59
3.2
2.61
13.27
Noticias
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Lipocine completa visitas de pacientes en ensayo fase 3 para tratamiento de DPP
Lipocine completes patient visits in phase 3 trial for PPD treatment
H.C. Wainwright eleva el objetivo de precio de las acciones de Lipocine a 15 dólares
H.C. Wainwright eleva precio objetivo de Lipocine a $15 por avance en ensayo PPD
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress
Lipocine completa inscripción en ensayo fase 3 para tratamiento de DPP
Lipocine completes enrollment in phase 3 trial for PPD treatment
Ensayo de medicamento para DPP de Lipocine continúa tras revisión positiva
El ensayo del fármaco PPD de Lipocine continúa tras revisión positiva de seguridad
Lipocine’s PPD drug trial continues after positive safety review
Lipocine alcanza el 80% de inscripción en ensayo de medicamento para depresión posparto